Summary Development of resistance to cytotoxic agents is a major limitation to their clinical use. Novel compounds are synthesized with a view to develop non-cross-resistant, less toxic and more potent activity. The detection of the anti-tumour properties of the inorganic compound cisplatin stimulated a broad search for other metal-containing complexes. Titanocene dichloride was synthesized on this basis and has shown potent anti-neoplastic activity in experimental animals. We have examined the in vitro activity of titanocene dichloride in two pairs of platinumsensitive and resistant human ovarian carcinoma cell lines, A2780/2780CP and CH1/CH1cisR, and in mutated p53-and bcl-2-transfected clones of A2780 cells. A time-and concentration-dependent anti-proliferative effect was observed in all cell lines treated with titanocene dichloride. The drug was found to significantly overcome platinum resistance in the 2780CP and the CH1 cisR cell lines and in the bcl-2 and the mutant p53 transfectants of A2780 cells. Titanocene dichloride induced a block in late S/early G2 phase of the cell cycle; however apoptotic cell death occurred from any phase of cycle. Titanium-DNA adducts were detected in A2780 cells treated with titanocene dichloride using atomic absorption spectrometry, suggesting that DNA may be a target for this drug. In agreement with this finding, p53 accumulated rapidly in drug-treated A2780 cells, indicative of a role for titanocene dichloride as a DNA-damaging agent. We have also performed studies to determine whether titanocene dichloride could demonstrate synergy with other cytotoxic agents in vitro. Isobologram analysis of cytotoxicity data obtained suggests that the combination of titanocene dichloride and 5-fluorouracil (5-FU) is synergistic. The potent in vivo anti-tumour activity of this compound, supported by the encouraging results from two phase clinical trials, suggests that titanocene dichloride could be a promising novel chemotherapeutic agent.
compounds are effective against essentially the same population of tumours (Gore et al, 1989; Eisenhauer et al, 1990; advanced Ovarian Cancer Trialists Group, 1991) . These reports, together with accumulating in vitro data suggest that carboplatin is not capable of circumventing cisplatin resistance. In addition to platinum, other metal-containing complexes have been synthesized and subjected to tumour screening. The antitumour activity of the organometallic compound titanocene dichloride [cyclopentadienyl-dichloro titanium(IV)] has been recognized and well documented in experimental animals. Thus, in a number of transplanted tumours of murine origin, such as Ehrlich ascites, sarcoma, colon adenocarcinoma, melanoma and lung carcinoma models, titanocene dichloride was highly effective Kopf-Maier, 1989a) . Moreover, the growth of xenotransplanted human tumours of colon, lung, breast and head and neck, as well as autochthonous chemically induced colorectal tumours in rats, were markedly reduced by this compound (Kopf-Maier et al, 1985; Kopf-Maier, 1987 , 1989b . The pattern of organ toxicity of titanocene dichloride in these animals was found to be different from that of cisplatin, with hepatic toxicity being the most prominent side-effect of titanocene; unlike cisplatin and carboplatin, however, no severe nephrotoxicity or myelotoxicity was observed (Kopf-Maier and Funke-Kaiser, 1986; Kopf-Maier and Geralch, 1986; K6pf-Maier, 1989a) .
Titanocene dichloride has recently entered phase I clinical trial with promising results (Christodoulou et al, submitted) . The doselimiting toxicities seen following a weekly schedule of 1-h infusion were reversible nephrotoxicity and hepatotoxicity. The pharmacokinetics of titanocene dichloride appear to be complex 2088 Titanocene: mechanistic studies 2089 and are described by a three-compartment model for total titanium.
Peak titanium levels are in the range 25-75 gM at the maximumtolerated dose of 140 mg m-2 per week.
While the anti-tumour effects of titanocene dichloride on experimental animals have been well documented and the phase I clinical trial so far suggests a potential role for this compound as an anti-tumour agent, little is known about its in vitro properties and mode of action (Harstrick et al, 1993) . In this study, we have demonstrated that titanocene dichloride confers potent anti-proliferative properties in vitro and may partly reverse platinum resistance in ovarian tumour cell lines. The cytostatic and cytotoxic effects of the drug could result from its observed ability to form DNA adducts and to induce cell cycle arrest and apoptosis. Understanding the mechanism of action of this novel chemotherapeutic agent may contribute to the development of more effective anti-cancer drugs.
MATERIALS AND METHODS Cell lines, plasmids, transfections
The human ovarian carcinoma cell line A2780 and the acquired platinum-resistant 2780CP (Behrens et al, 1987) were kindly provided by Dr J Plumb (University of Glasgow, Glasgow, UK). These lines were continuously maintained in RPMI medium supplemented with 10% fetal calf sesum (FCS) (Flow, UK), 1% glutamine and 1% penicillin/streptomycin. The CHI and CH1-cisR cell lines (Kelland et al, 1992) were kindly provided by Dr L Kelland (Institute for Cancer Research, Surrey, UK) and cultured in similar conditions. Development and characterization of A2780 clones expressing bc1-2 or temperature-sensitive p53 have been previously described (Eliopoulos et al, 1995) .
Anti-cancer agents and chemicals
Titanocene dichloride [cyclopentadienyl-dichloro-titanium(IV)] was provided by Medac (Hamburg, Germany). The formulation was supplied as a freeze-dried powder in vials containing 50 mg of drug. It was stored at 4°C, protected from light. The reconstitution of the compound was carried out in 0.9% sodium chloride at a concentration of 2 mg ml-'. The final solution was strictly protected from light and was used immediately. The structure of the drug is given in Figure 1 .
MTT assay for cytotoxicity Cytotoxicity was estimated using the colorimetric MTT conversion assay of Mosmann (1983) . Briefly, cells were trypsinized and plated out at a density of 3000-5000 cells per well into a 96-well plate and allowed to attach overnight. The next day, the cells were treated for 2 h with various concentrations of titanocene dichloride and/or other cytotoxic agents, washed with phosphate-buffered saline (PBS), and 200 tl of fresh complete medium were added.
Forty-eight hours later, 20 tl of 5 mg ml-' MTT (3,(4,4-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) (Sigma, Poole, UK) in PBS were added in each well incubated for 4 h at 37°C, and the formazan crystals fromed were dissolved in dimethyl sulphoxide (DMSO). The optical density (OD) was recorded at 550 nm on a Becton Dickinson Multisan. The IC90 (inhibitory concentration 50%) values were the drug concentrations inducing 50% reduction in the optical density.
[3H]Thymidine incorporation assay Cells were plated and treated as described above and pulsed for the last 4 h with 0.33 gCi [3H] Calculation of synergy A2780 cells were treated with various concentrations of titanocene dichloride (0, 10, 50, 100, 200 gM) in the presence of increasing concentrations of 5-fluorouracil (5-FU) (0, 10, 50, 100, 500 gM), doxorubicin (0, 0.1, 1, 5, 10 tM) or carboplatin (0, 10, 50, 100, 500 gM). Cytotoxicity was estimated using MTT conversion assays as described above. Synergy was calculated by isobologram analysis according to the method of Berenbaum (1981) .
Flow cytometric analysis of DNA content Cells in monolayer culture were harvested, washed, fixed in 1 % neutral-buffered formalin (NBF) and stained with 5 ,ug ml-' propidium iodide (PI). Fluorescence intensities were determined by quantitative flow cytometry and profiles were generated on a Coulter Epics-Profile II analyser. Coulter DNA-Cytologic Analysis software was used to calculate the cell cycle and S-phase fraction.
Assays for the detection of apoptotic cell death Quantification of DNA fragmentation was determined by flow cytometry using the TUNEL (TdT) assay, as previously described (Gorczyca et al, 1993; Eliopoulos et al, 1996) . A2780 cells treated with titanocene dichloride and untreated controls were fixed in 2% paraformaldehyde, permeabilized in 70% ethanol and incubated in 1 x TdT buffer containing 10 U of TdT (terminal deoxynucleotidyl transferase) (Gibco, UK) and 2 mm digoxigenin-11-dUTP (Boehringer, UK) for 35 min at 37°C, followed by a 30-min incubation with 0.1% Triton X-100 and 5% non-fat milk. The cells were finally stained with 5 mg ml-' propidium iodide (PI), and the P1 (red, x-axis) and FITC (green, y-axis) fluorescence were then analysed on a Becton Dickinson FACScan. Specific DNA fragmentation is the percentage green fluorescence in cells treated with titanocene dichloride after subtraction of background green fluorescence in control cultures.
For the electrophoretic characterization of DNA fragmentation, approximately 106 cells were lysed in a solution containing 10 mM EDTA, 50 mm Tris (pH 8), 0.5% N-Lauroyl-sarkosine (Sigma, Poole, UK) and 0.5 mg ml-' Proteinase-K (Boehringer) and incubated for 1 h in 50°C. RNAase at a concentration of 0.5 mg ml-' (Sigma, Poole, UK) was then added and the mixture was further incubated for 1 h. After the addition of 1O gl of a solution containing 0.01% bromophenol blue, 10 mm EDTA and 0.1% LMP agarose, the samples were analysed on a 2% agarose gel and visualized by ethidium bromide staining. Both attached and floating cells from titanocene dichloride-treated cultures were analysed.
DNA extraction
DNA extracts from tissue specimens were prepared as described by Sambrook et al (1989) , slightly modified (Eliopoulos and Spandidos, 1994 incubated overnight in lysis solution (10 mM Tris, pH 7.8, 150 mM sodium chloride, 0.5% sodium dodecyl sulphate (SDS) and 100 mg ml-' proteinase-K) at 37°C. After two phenol-chloroform extractions, the aqueous phase was removed and incubated for 2 h with 100 ,ug ml-' pancreatic RNAase (Sigma) at 37°C and for an additional 2-h period with 100 ltg ml-' proteinase-K (Boehringer) followed by phenol-chloroform extraction twice. The aqueous phase was then removed and the DNA was precipitated with ethanol. The DNA was washed with 70% ethanol, dried briefly, resuspended in sterile water and estimated photometrically at 260 nm using an LKB 4054 spectrophotometer.
Detection of titanium-DNA adducts DNA-bound titanium was measured using electrothermal atomization atomic absorption spectrometry on a Varian Spectra AA-400 equipped with deuterium background correction. Analysis was performed directly after dilution of the DNA solutions with 0.1% HNO3. For calibration identically-treated matrix-matched standards were used. Standards were prepared using inorganic titanium (BDH, Poole, UK), the analytical behaviour of this form of the element having been found to match that of titanium present in solutions of titanocene dichloride in 0. 1% nitric acid. Over the last few years, there has been increasing evidence that expression of certain anti-apoptotic genes, such as bcl-2 and p53, may affect the cellular response to chemotherapy and therefore modulate the sensitivity of cells to anti-cancer drugs (Dive and Hickman, 1991; Dive and Wyllie, 1993; Martin and Green, 1994) . Thus, we have recently shown that bcl-2 and p53 are frequently expressed in ovarian carcinomas (Herod et al, 1996) , and cisplatin-resistant ovarian tumour cell lines have elevated levels of these anti-apoptotic proteins compared with their normal counterparts (Eliopoulos et al, 1995) . In addition, transfection of A2780 cells with a bcl-2-or a temperature-sensitive mutant p53 (ts p53)-expressing plasmid increased platinum resistance by 2.1 to 3.5-and 1.7-to 2.4-fold respectively (Eliopoulos et al, 1995) .
Protein extraction and Western blot analysis
Examination of two of these bcl-2 clones (A2780bcl-2/Cl. 10 and Cl. 14) for response to titanocene dichloride showed that this drug may be very effective against resistance conferred by bcl-2. In each experiment performed, the dose-response curve of titanocene-treated A2780bcl-2/Cl. 14 vs A2780 cells was consistently shifted to the right ( Figure 2B and C) , which suggests that bcl-2 confers some degree of resistance; however the difference in IC50 values is too small to support a biological significance. Thus, while cisplatin-treated A2780bcl-2 cells were approximately three-fold more resistant than the parental line, the resistant factor for titanocene-treated bcl-2-expressing cells was 1.2 (Table 1) , which suggests that titanocene dichloride may overcome bcl-2-mediated platinum resistance.
As mutated p53 confers a survival advantage against chemotherapy (Hainaut, 1995) 
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Tflm (h) The percentage of apoptotic cells is given on the top right-hand side of the graphs dose-response curves for mutated p53-expressing vs control in cisplatin resistance (Eliopoulos et al, 1995) , these results A2780 cells were almost identical ( Figure 2B 33.6 at 15 and 24 h respectively. 2780CP and A2780bcl-2/Cl.14 cells were also examined for cell cycle block upon titanocene treatment and gave similar results ( Figure 3B ).
Titanocene dichloride induces apoptosis in ovarian tumour cell lines
Apoptosis is a mode of cell death observed in a variety of cell types after treatment with chemotherapeutic agents. In order to determine whether titanocene dichloride also induces apoptosis in vitro, A2780 cells were treated for 2 h with 1 x 10-5 M, 1 x 104 M or I x l0-M titanocene and analysed 24 h later for DNA fragmentation using agarose gel electrophoresis. Formation of small-molecular-weight DNA (DNA ladders) is a hallmark of apoptotic cell death. As shown in Figure 4A , titanocene dichloride induced formation of DNA ladders at 1 x I O-3 M and to a lesser extent at 1 x 104 M but not at the lower concentration of 1 x 10-5 M. DNA ladders were not detected in control, untreated cultures ( Figure 4A , lane 1). As this agarose electrophoresis assay does not allow correlation between DNA fragmentation and position in the cell cycle, the British Journal of Cancer (1998) TdT (TUNEL) assay was performed to determine whether titanocene-treated A2780 cells apoptose at specific phases of the cell cycle. A2780 cells were exposed to 1 x 10-3 M titanocene dichloride for 2 h and analysed 6, 15 or 24 h later for DNA strand breaks and DNA content, as described in Materials and methods. Double-colour flow cytometric analysis showed a significant increase in green-fluorescent apoptotic cells at 15 and 24 h and revealed that titanocene induces apoptosis from any phase of the cell cycle ( Figure 4B ).
Formation of titanium-DNA adducts and up-regulation of p53 in titanocene-treated A2780 cells Previous studies have documented that DNA is the primary target for cisplatin and that formation of platinum-DNA adducts is necessary for the cytotoxic action of the drug. In order to determine whether titanocene dichloride also forms DNA adducts, A2780 cells were exposed to 1 x 10-3 M titanocene dichloride for 2, 6 or 15 h, and DNA was extracted and purified using a standard procedure. Titanium bound to DNA was then measured using atomic absorption spectrometry. Titanium was detected in DNA isolated from titanocene dichloride-treated but not in DNA from untreated control cells ( Figure 5A ). In addition, the accumulation of titanium-DNA adducts increased with the duration of the exposure to the drug, being most prominent at 15 h.
As formation of platinum-DNA complexes and subsequent DNA damage lead to nuclear accumulation of p53 (Kastan et al, 1991; Eliopoulos et al, 1995) , the effect of titanocene on p53 levels in A2780 cells was determined. Protein extracts isolated from titanocene-treated cells were subjected to immunoblot analysis using an anti-p53-specific monoclonal antibody. As shown in Figures Titanocene dichloride exhibits synergistic cytotoxicity with 5-FU The observed lack of myelosuppression in animal models makes titanocene dichloride a clinically interesting cytotoxic compound as it could potentially allow combinations with other drugs. To determine whether titanocene could exhibit synergy with other agents commonly used in cancer chemotherapy, A2780 cells were exposed to combinations of titanocene dichloride with 5-fluorouracil (5-FU), doxorubicin or carboplatin. Interestingly, low concentrations of titanocene, which have little or no effect on A2780 viability, significantly potentiated the antiproliferative action of 5-FU ( Figure 6A ). Isobologram analysis revealed synergy with this compound ( Figure 6B ). Titanocene The in vivo anti-tumour activity of the organometallic compound titanocene dichloride has been previously documented in experimental animals, however little is known about its mode of action. Our studies indicate that this drug exhibits limited antiproliferative activity in vitro, compared with platinum compounds commonly used in chemotherapeutic regimens. Thus, in A2780 and CH1 ovarian tumour cell lines, titanocene appears to be approximately 100-and twofold less potent than cisplatin and carboplatin respectively. Interestingly, however, titanocene dichloride was found to significantly overcome cisplatin resistance in ovarian carcinoma cell lines. Thus, while 2780CP cells are 12.7-fold more resistant to cisplatin than their parental, sensitive counterpart, they were found to be only 1.5-fold more resistant in response to titanocene. As platinum resistance in 2780CP and CH1 -cisR cells involves predominantly increased DNA repair, the cytotoxic action of titanocene may involve mechanisms different from those of cisplatin. In this context, it is interesting that, while cisplatin is known to mediate an early S-phase block in a number of cell lines, including A2780 (Andrews and Howell, 1990; Eliopoulos et al, 1995) , titanocene dichloride induced a late S/ early G, phase block in the cell cycle. The G, arrest may represent a phase at which repair of damage occurs before the drug-treated cells enter mitosis.
The observed IC 50 values of titanocene dichloride were in the range 200-800 gM, which are in agreement with a previous report (Hastrick et al, 1993) . While its in vitro antiproliferative effects are rather limited, titanocene dichloride has demonstrated impressive in vivo activity as measured by tumour regression in animal models. In addition, our phase I clinical trial data with this compound has shown that blood peak levels of titanium are in the range 25-75 gM and anti-tumour activity was seen (Christodoulou et al, submitted) . At present it is unclear why titanocene dichloride appears to be more potent in vivo rather than in vitro. While this compound is stable at low pH (pH < 3), it undergoes rapid aquation at physiological pH and formation of an as yet undetected drug metabolite in vivo is possible. Clinical drug resistance is likely to be multifactorial but a unifying feature may well be the failure of tumour cells to engage the process of apoptosis (Dive and Hickman, 1991; Dive and Wyllie, 1993; Martin and Green, 1994) , and certain gene products are known to influence this event. Thus, overexpression of bcl-2 in high-grade follicular lymphomas due to a t(14;18) translocation may be associated with development of resistance to chemotherapy. While the role of bcl-2 in regulation of drug-induced apoptosis is supported by a number of in vitro studies in haemopoietic cell systems, the effect of this protein on the sensitivity of carcinoma cells to chemotherapy remains less known. Expression of mutated p53 has also been shown to protect from apoptosis, although not to the same extent as bcl-2 (Hainaut, 1995) . We have previously shown that ovarian carcinoma cells that are resistant to cisplatin naturally overexpress bcl-2, p53 or both proteins, suggesting an important role for these genes in acquired resistance (Eliopoulos et al, 1995) . Expression of exogenous bcl-2 or mutated p53 in the ovarian cell line A2780 also British Journal of Cancer (1998) 77(12), [2088] [2089] [2090] [2091] [2092] [2093] [2094] [2095] [2096] [2097] . Cancer Research Campaign 1998 2096 CV Christodoulou et al resulted in decreased sensitivity to cisplatin. Interestingly, treatment of A2780 cells transfected with bcl-2 or mutated p53 with high concentrations of titanocene dichloride, abrogated platinum resistance mediated by these anti-apoptotic proteins. The above observations may be important for the therapy of tumours that develop resistance to platinum, and we are currently examining this possibility in experimental animals bearing 2780CP-or A2780bcl-2-based tumours.
While the cytostatic effects of titanocene dichloride could be attributed to a specific block in the cell cycle, it appears that the drug induces cell killing from any phase of cycle. Similar results have been reported for some but not all anti-cancer drugs. DNA is the critical target for cisplatin and various platinum-DNA adducts are known to be formed in cell lines treated with this drug (i.e. monofunctional, intrastrand, interstrand, intermolecular) (Roberts et al, 1986; Andrews and Howell, 1990) . Interestingly, formation of titanocene-DNA adducts was also observed in titanocene dichloride-treated A2780 cells. The nature of these adducts is under investigation. Preliminary results indicate a significant timeand dose-dependent formation of DNA single strand breaks but only a very low amount of DNA cross-linking in drug-treated cells. Formation of DNA cross-linking was also observed in isolated DNA treated in vitro with titanocene; however this effect was found to be significantly lower than that of cisplatin (JA Hartley, AG Eliopoulos and DJ Kerr, unpublished observations). Titanocene-DNA adducts may directly mediate DNA damage, which could lead to nuclear accumulation of p53. Previous studies have documented the rapid induction of p53 in response to DNAdamaging agents, including UV radiation and various chemotherapeutic agents, and have attributed to p53 the role of the 'guardian of the genome' (Kastan et al, 1991; Lane, 1992) . In agreement with these reports, titanocene dichloride was found to induce nuclear accumulation of p53 in a dose-and time-dependent manner. Glutathione depletion using Buthionine sulphoximin (BSO) leads to an increase in titanocene dichloride-mediated cytotoxicity (Harstrick et al, 1993) , and our preliminary results suggest that treatment of A2780 cells with titanocene dichloride in the presence of BSO significantly enhances p53 accumulation.
Titanocene dichloride has an interesting toxicological profile and does not cause myelosuppression; therefore it could be safely combined with other cytotoxics. A potentially interesting observation from a clinical point of view is that titanocene dichloride demonstrates synergy with 5-FU, a thymidylate synthetase inhibitor, in conferring cytotoxic effects in A2780 cells. No synergistic interaction was found, however, with carboplatin or doxorubicin. This may be particularly important for the treatment of metastatic colon adenocarcinoma, as there is lack of effective treatment for this type of malignancy. 5-FU is the cornerstone of therapeutic regimes against colon cancer but it produces only a 15-30% response rate in combination with leucovorin. Similar response rates are produced by tomudex, which is a new thymidylate synthetase inhibitor with a more favourable toxicological profile and a more convenient way of administration. Oxaliplatin, a novel platinum analogue, which, in combination with 5-FU/folinic acid, has shown promising results in phase II and III clinical trials (Levi et al, 1995) , has demonstrated potent cytotoxic activity against colorectal carcinoma cell lines either alone or in synergy with 5-FU. In addition, human colon xenografts have been highly sensitive to oxaliplatin and no cross-resistance to cisplatin has been observed (Mathe et al, 1989; Tashiro et al, 1989; Dorr and Von Hoff, 1993; Pendyala and Creaven, 1993) . By analogy, Kopf-Maier and colleagues (1985) have demonstrated impressive anti-tumour activity of titanocene dichloride against human tumour xenografts of colon adenocarcinoma, and our preliminary in vitro data suggest that this drug is also effective against a number of colon cancer cell lines. As we have noted a synergistic effect with 5-FU and titanocene dichloride, it would be particularly attractive to test this combination in metastatic colorectal cancer. Studies addressing this question in experimental animals are under way.
In summary, titanocene dichloride is a novel drug with interesting in vitro characteristics. The elucidation of its precise mechanism of action may lead to the rational development of other more active titanium analogues. So far, titanocene dichloride has been tested in two phase I clinical trials, one in Germany (Kortel et al, 1996) and another in our Institute (Christodoulou et al, submitted), which have given promising results, and we plan a phase II study in metastatic colon cancer in combination with 5-FU.
